메뉴 건너뛰기




Volumn 13, Issue 12, 2007, Pages 3713-3723

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXEL 7647; GEFITINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

EID: 34250791359     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2590     Document Type: Article
Times cited : (79)

References (39)
  • 1
    • 22044442973 scopus 로고    scopus 로고
    • Tyrosine kinases as targets for cancer therapy
    • Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
    • (2005) N Engl J Med , vol.353 , pp. 172-187
    • Krause, D.S.1    Van Etten, R.A.2
  • 2
    • 15544381413 scopus 로고    scopus 로고
    • Receptor tyrosine kinases and anticancer therapy
    • Medinger M, Drevs J. Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 2005;11:1139-49.
    • (2005) Curr Pharm Des , vol.11 , pp. 1139-1149
    • Medinger, M.1    Drevs, J.2
  • 3
    • 0034722889 scopus 로고    scopus 로고
    • The EGF receptor family as targets for cancer therapy
    • Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
    • (2000) Oncogene , vol.19 , pp. 6550-6565
    • Mendelsohn, J.1    Baselga, J.2
  • 4
    • 14644445166 scopus 로고    scopus 로고
    • Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives
    • Spano JP, Fagard R, Soria JC, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005;16:189-94.
    • (2005) Ann Oncol , vol.16 , pp. 189-194
    • Spano, J.P.1    Fagard, R.2    Soria, J.C.3
  • 6
    • 0032529048 scopus 로고    scopus 로고
    • Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein
    • Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 1998;334:189-95.
    • (1998) Biochem J , vol.334 , pp. 189-195
    • Kim, H.H.1    Vijapurkar, U.2    Hellyer, N.J.3    Bravo, D.4    Koland, J.G.5
  • 7
    • 0036479747 scopus 로고    scopus 로고
    • Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival
    • Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002;7:d376-89.
    • (2002) Front Biosci , vol.7
    • Grant, S.1    Qiao, L.2    Dent, P.3
  • 8
    • 0034799139 scopus 로고    scopus 로고
    • A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
    • Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
    • (2001) Clin Cancer Res , vol.7 , pp. 2958-2970
    • Ciardiello, F.1    Tortora, G.2
  • 9
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 10
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3
  • 11
    • 0034954124 scopus 로고    scopus 로고
    • The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy
    • Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
    • (2001) Ann Oncol , vol.12 , pp. 745-760
    • Pedersen, M.W.1    Meltorn, M.2    Damstrup, L.3    Poulsen, H.S.4
  • 12
    • 0028863853 scopus 로고
    • Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
    • Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251-9.
    • (1995) Cell Growth Differ , vol.6 , pp. 1251-1259
    • Batra, S.K.1    Castelino-Prabhu, S.2    Wikstrand, C.J.3
  • 13
    • 19944427851 scopus 로고    scopus 로고
    • Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
    • Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
    • (2005) Cancer Res , vol.65 , pp. 226-235
    • Amann, J.1    Kalyankrishna, S.2    Massion, P.P.3
  • 14
    • 18244371651 scopus 로고    scopus 로고
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2005;2:e73.
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2005;2:e73.
  • 15
    • 14644440555 scopus 로고    scopus 로고
    • Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
    • (2005) J Clin Oncol , vol.23 , pp. 1011-1027
    • Hicklin, D.J.1    Ellis, L.M.2
  • 17
    • 4644290521 scopus 로고    scopus 로고
    • Eph receptor tyrosine kinases in tumor and tumor microenvironment
    • Brantley-Sieders D, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004;10:3431-42.
    • (2004) Curr Pharm Des , vol.10 , pp. 3431-3442
    • Brantley-Sieders, D.1    Parker, M.2    Chen, J.3
  • 18
    • 2442421790 scopus 로고    scopus 로고
    • Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
    • Liu W, Jung YD, Ahmad SA, et al. Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer. Br J Cancer 2004;90:1620-6.
    • (2004) Br J Cancer , vol.90 , pp. 1620-1626
    • Liu, W.1    Jung, Y.D.2    Ahmad, S.A.3
  • 19
    • 0842282623 scopus 로고    scopus 로고
    • Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist
    • Dobrzanski P, Hunter K, Jones-Bolin S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004;64:910-9.
    • (2004) Cancer Res , vol.64 , pp. 910-919
    • Dobrzanski, P.1    Hunter, K.2    Jones-Bolin, S.3
  • 20
    • 0037093097 scopus 로고    scopus 로고
    • Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior
    • Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7.
    • (2002) Cancer Res , vol.62 , pp. 2840-2847
    • Carles-Kinch, K.1    Kilpatrick, K.E.2    Stewart, J.C.3    Kinch, M.S.4
  • 21
    • 21144433227 scopus 로고    scopus 로고
    • EphB4 expression and biological significance in prostate cancer
    • Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res 2005;65:4623-32.
    • (2005) Cancer Res , vol.65 , pp. 4623-4632
    • Xia, G.1    Kumar, S.R.2    Masood, R.3
  • 22
    • 0036785161 scopus 로고    scopus 로고
    • Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis
    • Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002;59:58-67.
    • (2002) Microsc Res Tech , vol.59 , pp. 58-67
    • Nakamoto, M.1    Bergemann, A.D.2
  • 23
    • 0034693857 scopus 로고    scopus 로고
    • Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis
    • Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000;19:5614-9.
    • (2000) Oncogene , vol.19 , pp. 5614-5619
    • Dodelet, V.C.1    Pasquale, E.B.2
  • 24
    • 20444431504 scopus 로고    scopus 로고
    • The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade
    • Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005;15:4521-32.
    • (2005) Clin Cancer Res , vol.15 , pp. 4521-4532
    • Sini, P.1    Wyder, L.2    Schnell, C.3
  • 25
    • 18844365440 scopus 로고    scopus 로고
    • Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors
    • Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005;91:187-201.
    • (2005) Breast Cancer Res Treat , vol.91 , pp. 187-201
    • Chan, C.T.1    Metz, M.Z.2    Kane, S.E.3
  • 26
    • 33645735004 scopus 로고    scopus 로고
    • Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
    • Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
    • (2006) Cancer Res , vol.66 , pp. 3639-3648
    • Franco, M.1    Man, S.2    Chen, L.3
  • 27
    • 7044234484 scopus 로고    scopus 로고
    • Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: Implications for therapy
    • Chelouche-Lev D, Miller CP, Tellez C, et al. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004;40:2509-18.
    • (2004) Eur J Cancer , vol.40 , pp. 2509-2518
    • Chelouche-Lev, D.1    Miller, C.P.2    Tellez, C.3
  • 28
    • 0032016685 scopus 로고    scopus 로고
    • EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells
    • Fan W H, Lu YL, Deng F, et al. EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells. Cell Res 1998;8:63-71.
    • (1998) Cell Res , vol.8 , pp. 63-71
    • Fan, W.H.1    Lu, Y.L.2    Deng, F.3
  • 29
    • 34250761075 scopus 로고    scopus 로고
    • Receptor-type kinase modulators and methods of use
    • United States patent WO2004006846, Jan 22
    • Rice KD, Anand NK, Bussenius J, et al. Receptor-type kinase modulators and methods of use. United States patent WO2004006846. 2004 Jan 22.
    • (2004)
    • Rice, K.D.1    Anand, N.K.2    Bussenius, J.3
  • 30
    • 0035939330 scopus 로고    scopus 로고
    • Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
    • Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
    • (2001) Bioorg Med Chem Lett , vol.11 , pp. 1911-1914
    • Barker, A.J.1    Gibson, K.H.2    Grundy, W.3
  • 31
    • 34250715588 scopus 로고    scopus 로고
    • Preparation of
    • N-phenylquinazoline-4-amines as neoplasm inhibitors. United States patent WO9630347. 1996 Oct. 03
    • Schnur RC, Arnold LD. Preparation of N-phenylquinazoline-4-amines as neoplasm inhibitors. United States patent WO9630347. 1996 Oct. 03.
    • Schnur, R.C.1    Arnold, L.D.2
  • 32
    • 0026351375 scopus 로고
    • Activation of the autocrine transforming growth factor a pathway in human squamous carcinoma cells
    • Reiss M, Stash EB, Vellucci VF, Zhou ZL. Activation of the autocrine transforming growth factor a pathway in human squamous carcinoma cells. Cancer Res 1991;51:6254-62.
    • (1991) Cancer Res , vol.51 , pp. 6254-6262
    • Reiss, M.1    Stash, E.B.2    Vellucci, V.F.3    Zhou, Z.L.4
  • 33
    • 0034234854 scopus 로고    scopus 로고
    • Tumor inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
    • Klapper LN, Waterman H, Sela M, Yarden Y. Tumor inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-8.
    • (2000) Cancer Res , vol.60 , pp. 3384-3388
    • Klapper, L.N.1    Waterman, H.2    Sela, M.3    Yarden, Y.4
  • 34
    • 20844460619 scopus 로고    scopus 로고
    • A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
    • Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-9.
    • (2004) Cancer Res , vol.64 , pp. 5913-5919
    • Chen, L.L.1    Trent, J.C.2    Wu, E.F.3
  • 35
    • 0141599428 scopus 로고    scopus 로고
    • Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
    • Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-72.
    • (2002) J Biol Chem , vol.277 , pp. 46265-46272
    • Stamos, J.1    Sliwkowski, M.X.2    Eigenbrot, C.3
  • 36
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3
  • 37
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3
  • 38
    • 23844444080 scopus 로고    scopus 로고
    • An alternative inhibitor overcomes resistance caused by amutation of the epidermal growth factor receptor
    • Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by amutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101.
    • (2005) Cancer Res , vol.65 , pp. 7096-7101
    • Kobayashi, S.1    Ji, H.2    Yuza, Y.3
  • 39
    • 21144439000 scopus 로고    scopus 로고
    • Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    • Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 7665-7670
    • Kwak, E.L.1    Sordella, R.2    Bell, D.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.